Dovato Medical Information- Our HIV Medications

Prescribing Information, including boxed warning

Patient Information

Talk to a Medical Expert

Frequently Requested Documents

MI Letters

Resistance Data for Dovato Treatment naive Clinical Trials

Use of Dovato in Real-world Settings

Use of Dovato in Treatment Experienced Patients Including Those Who Are Virologically Suppressed

Weight changes in patients on DTG-based regimens

Dosing of Dovato in Patients with Renal Impairment

Infographics

Use of Dovato in Patients With the M184V/I Resistance Mutation

Infographic: Impact of Adherence on Efficacy of Dovato

Inflammatory Biomarkers During Treatment with Dovato

Infographic: Use of Dovato in Real-world Settings

Use of Dovato in 'Test and Treat' Strategy: The STAT Study

Medical Information Documents
Recent Congress Data
On Demand Medical Videos
Congress Data

Utilizing and Applying Findings from Observational Studies in AIDS Research
Shelly Dhir, PharmD Sr. Director, Portfolio Medical Lead
Dr. Rick Elion, MD Director of Clinical Research, Washington Health Institute and Clinical Professor of Medicine George Washington University School of Medicine

Using Fewer HIV Treatments When Treating HIV Long Term
Andrew Zolopa, MD VP, Head, North American Medical Affairs ViiV Healthcare
Dr. Babafemi Taiwo, MD, MBBS Gene Stollerman Professor of Medicine and Chief of the Division of Infectious Diseases Northwestern University

DTG/3TC: Real-World Evidence
An Update from CROI 2020
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

DTG: Metabolic Data Update
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study
Mark Underwood, Clinical Virologist and Development Investigator

TANGO Study: Metabolic Substudy
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

DTG/3TC: Barrier to Resistance
Jan van Lunzen, Head of Translational Medical Research

Post-CROI 2021 Webinar
Andrew Zolopa, MD, VP, Head, North America Medical Affairs

GEMINI 144 Week: Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

TANGO 96 Week: Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

GEMINI 48 Week: Adherence Analysis
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

STAT 24 Week: Feasibility, Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Clinical Trials Data

Using Fewer HIV Treatments When Treating HIV Long Term
Andrew Zolopa, MD VP, Head, North American Medical Affairs ViiV Healthcare
Dr. Babafemi Taiwo, MD, MBBS Gene Stollerman Professor of Medicine and Chief of the Division of Infectious Diseases Northwestern University

The Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1
GEMINI-1 and GEMINI-2 Studies
Michael Aboud, VP, Global Medical Lead, Dolutegravir

Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study
Mark Underwood, Clinical Virologist and Development Investigator

TANGO Study: Metabolic Substudy
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

STAT Study: The Feasibility, Efficacy and Safety of Dovato in a Test-and-Treat Setting
Andrew Zolopa, MD, VP, Head, North America Medical Affairs

Post-CROI 2021 Webinar
Andrew Zolopa, MD, VP, Head, North America Medical Affairs

GEMINI 144 Week: Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

TANGO 96 Week: Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

GEMINI 48 Week: Adherence Analysis
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

STAT 24 Week: Feasibility, Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Safety

Post-CROI 2021 Webinar
Andrew Zolopa, MD, VP, Head, North America Medical Affairs

DTG: Metabolic Data Update
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

TANGO Study: Metabolic Substudy
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Antiretroviral Therapy and Weight Gain
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Virology/Resistance

Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study
Mark Underwood, Clinical Virologist and Development Investigator

DTG/3TC: Barrier to Resistance
Jan van Lunzen, Head of Translational Medical Research

Real World Evidence

Utilizing and Applying Findings from Observational Studies in AIDS Research
Shelly Dhir, PharmD Sr. Director, Portfolio Medical Lead
Dr. Rick Elion, MD Director of Clinical Research, Washington Health Institute and Clinical Professor of Medicine George Washington University School of Medicine

DTG/3TC: Real-World Evidence
An Update from CROI 2020
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Treatment Naïve Data (GEMINI 1 & 2 Studies)

Using Fewer HIV Treatments When Treating HIV Long Term
Andrew Zolopa, MD VP, Head, North American Medical Affairs ViiV Healthcare
Dr. Babafemi Taiwo, MD, MBBS Gene Stollerman Professor of Medicine and Chief of the Division of Infectious Diseases Northwestern University

Week 48 Results

Year 3 Subgroup Analysis (CROI 2021)

Suppressed Switch Data

TANGO Study

Metabolic Substudy (Video)

Target Not Detected Results

Week 96 Subgroup Analyses

Are you a US healthcare provider?

This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.

If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.

Yes